Skip to main content
Journal cover image

Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease.

Publication ,  Journal Article
Hill, KD; Baldwin, HS; Bichel, DP; Ellis, AM; Graham, EM; Hornik, CP; Jacobs, JP; Jaquiss, RDB; Jacobs, ML; Kannankeril, PJ; Li, JS; Torok, R ...
Published in: Am Heart J
August 2020

BACKGROUND: Randomized controlled trials (RCTs) in children with heart disease are challenging and therefore infrequently performed. We sought to improve feasibility of perioperative RCTs for this patient cohort using data from a large, multicenter clinical registry. We evaluated potential enrollment and end point frequencies for various inclusion cohorts and developed a novel global rank trial end point. We then performed trial simulations to evaluate power gains with the global rank end point and with use of planned covariate adjustment as an analytic strategy. METHODS: Data from the Society of Thoracic Surgery-Congenital Heart Surgery Database (STS-CHSD, 2011-2016) were used to support development of a consensus-based global rank end point and for trial simulations. For Monte Carlo trial simulations (n = 50,000/outcome), we varied the odds of outcomes for treatment versus placebo and evaluated power based on the proportion of trial data sets with a significant outcome (P < .05). RESULTS: The STS-CHSD study cohort included 35,967 infant index cardiopulmonary bypass operations from 103 STS-CHSD centers, including 11,411 (32%) neonatal cases and 12,243 (34%) high-complexity (Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery mortality category ≥4) cases. In trial simulations, study power was 21% for a mortality-only end point, 47% for a morbidity and mortality composite, and 78% for the global rank end point. With covariate adjustment, power increased to 94%. Planned covariate adjustment was preferable to restricting to higher-risk cohorts despite higher event rates in these cohorts. CONCLUSIONS: Trial simulations can inform trial design. Our findings, including the newly developed global rank end point, may be informative for future perioperative trials in children with heart disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

August 2020

Volume

226

Start / End Page

188 / 197

Location

United States

Related Subject Headings

  • Research Design
  • Randomized Controlled Trials as Topic
  • Humans
  • Heart Diseases
  • Child
  • Cardiovascular System & Hematology
  • Cardiopulmonary Bypass
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hill, K. D., Baldwin, H. S., Bichel, D. P., Ellis, A. M., Graham, E. M., Hornik, C. P., … O’Brien, S. M. (2020). Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease. Am Heart J, 226, 188–197. https://doi.org/10.1016/j.ahj.2020.05.011
Hill, Kevin D., H Scott Baldwin, David P. Bichel, Alicia M. Ellis, Eric M. Graham, Christoph P. Hornik, Jeffrey P. Jacobs, et al. “Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease.Am Heart J 226 (August 2020): 188–97. https://doi.org/10.1016/j.ahj.2020.05.011.
Hill KD, Baldwin HS, Bichel DP, Ellis AM, Graham EM, Hornik CP, et al. Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease. Am Heart J. 2020 Aug;226:188–97.
Hill, Kevin D., et al. “Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease.Am Heart J, vol. 226, Aug. 2020, pp. 188–97. Pubmed, doi:10.1016/j.ahj.2020.05.011.
Hill KD, Baldwin HS, Bichel DP, Ellis AM, Graham EM, Hornik CP, Jacobs JP, Jaquiss RDB, Jacobs ML, Kannankeril PJ, Li JS, Torok R, Turek JW, O’Brien SM. Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease. Am Heart J. 2020 Aug;226:188–197.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

August 2020

Volume

226

Start / End Page

188 / 197

Location

United States

Related Subject Headings

  • Research Design
  • Randomized Controlled Trials as Topic
  • Humans
  • Heart Diseases
  • Child
  • Cardiovascular System & Hematology
  • Cardiopulmonary Bypass
  • 3201 Cardiovascular medicine and haematology
  • 1117 Public Health and Health Services
  • 1102 Cardiorespiratory Medicine and Haematology